用一种新型β受体阻滞剂对心绞痛患者进行长期治疗（作者译）
[Longterm therapy of angina pectoris patients with a new beta-receptor blocker (author's transl)].
作者信息
Schaumann H J, Diekmann H J, Neuss H, Stegaru B
出版信息
MMW Munch Med Wochenschr. 1976 Sep 3;118(36):1123-5.
PMID:9583
Abstract
The beta-receptor blocker Timolol was investigated for 28 weeks in a double blind trial and then for up to 100 weeks in an open trial in patients with angina pectoris. In both phases of the investigation. Timolol caused a quite marked regression in the frequency of attacks and in the pulse rate at rest. The evaluation of therapeutic success by doctor and patient was positive for Timolol.
摘要
在一项双盲试验中对β受体阻滞剂噻吗洛尔进行了28周的研究，随后在一项开放性试验中对心绞痛患者进行了长达100周的研究。在研究的两个阶段，噻吗洛尔均使发作频率和静息脉搏率出现相当明显的下降。医生和患者对噻吗洛尔治疗效果的评价均为阳性。
Zotero 插件